Nippon India Nifty Pharma ETF share price
AMFI: 149008ISIN: INF204KC1089Nippon India Mutual FundETFs
Close ₹25.89down ₹0.34 (1.30%)
Close on 23 Oct 2026, traded as PHARMABEES.
- NAV, 22 Oct 2026Net asset value (NAV). What one unit of the fund is worth: everything the fund owns, less what it owes, divided by the units held by investors, worked out once a day after the market closes.
- ₹26.3166
- Discount to NAV, 22 Oct 2026Premium or discount. How far the ETF's closing price on the exchange was above or below its NAV the same day: the close divided by that day's NAV, less one. Above the NAV is a premium, below it a discount.
- −0.33%
- Day's rangeDay's range. The lowest and the highest price the ETF traded at in the session.
- ₹25.70 to ₹26.88
- VolumeVolume. Units of the ETF traded on the exchange in the session.
- 41,19,128
52-week range of traded prices to 23 Oct 2026
₹21.69Low, 2 Apr 2026₹28.58High, 24 Sep 2026
- Fund sizeAssets under management. The money the fund manages for all its investors, across every plan, at the end of the month.
- ₹1,736 CrSep 2026
- Expense ratioTotal expense ratio. What the fund charges each year as a share of the money invested, taken out of the NAV every day, so the returns shown are already after it.
- 0.23%19 Oct 2026
- Exit loadExit load. A charge, as a share of the amount redeemed, on units sold before a set period has passed since they were bought.
- None
- P/EP/E. What the fund pays for each rupee of yearly profit its companies earn: the total value of its shares divided by those companies' last four quarters of profit, each in proportion to what the fund holds. The profit leaves out one-off items (exceptional items and businesses sold or demerged), so one company's one-off gain cannot make the fund look cheap. A loss-making company lowers the profit. Shown when at least 80% of the fund's shares are counted.
- 37.030 Sep 2026
- Risk levelRiskometer. The fund's own risk label on SEBI's six-step scale, from Low to Very High, set from what the fund holds and reviewed every month.
- Very HighAug 2026
- HoldingsHoldings. The number of different securities in the fund's latest monthly portfolio: shares, bonds, money market paper and units of other funds, not cash, overnight lending or futures.
- 2030 Sep 2026
- LaunchedLaunch date. The day the fund first allotted units to investors, at the close of its new fund offer.
- 2 Jul 2021
Nippon India Nifty Pharma ETF returns
Over each window to 22 Oct 2026
| Over | ReturnTrailing return. The change in NAV from the start date to the latest NAV; over a year and longer, the yearly rate that would compound to the same change (CAGR). | BenchmarkBenchmark. The index the fund house chose to measure the fund against, in its total return form, with dividends added back. |
|---|---|---|
| 1 week | −0.86% | −0.86% |
| 1 month | −4.89% | −4.88% |
| 3 months | −0.57% | −0.51% |
| 6 months | +14.25% | +14.39% |
| 1 year | +14.39% | +14.67% |
| 3 years | +19.64% | +19.95% |
| 5 years | +13.46% | +13.72% |
| 10 years | Needs 10 years | – |
₹10,000 put in on 6 Jul 2021 is ₹18,263 at the NAV of 22 Oct 2026Growth of ₹10,000. What ₹10,000 put in at the NAV of the first day would be worth at the latest NAV, after the fund's expenses and before tax and any exit load.Over a year and longer, a return is the yearly rate. Benchmark: Nifty Pharma TRI, over the same days as the fund.
At the month end, 30 Sep 2026
| Over | FundTrailing return. The change in NAV from the start date to the latest NAV; over a year and longer, the yearly rate that would compound to the same change (CAGR). | BenchmarkBenchmark return. The change in the benchmark index's total return level over the same dates as the fund's return, as a yearly rate over a year and longer. |
|---|---|---|
| 1 year | +23.68% | +23.98% |
| 3 years | +20.13% | +20.43% |
| 5 years | +13.38% | +13.63% |
| Since launch | +12.88% | +13.15% |
Benchmark: Nifty Pharma TRI. Both as the fund house states them for the month.
Return in each calendar year
- FundCalendar year return. The change in NAV from the last NAV of one year to the last NAV of the next.
- Nifty Pharma TRIBenchmark return. The change in the benchmark index's total return level over the same dates as the fund's return, as a yearly rate over a year and longer.
- Loss
Highest year to Dec 2024, +39.6%; lowest year to Dec 2022, −10.9%Above the benchmark in 0 of 4 years
Rolling returns
Per cent a year, every window from 6 Jul 2021 to 22 Oct 2026
Lowest to highestAverage
LowestLowest rolling return. The worst yearly return of any window of this length in the fund's history, one window starting on each day it priced.AverageAverage rolling return. The average of the yearly returns of every window of this length in the fund's history.HighestHighest rolling return. The best yearly return of any window of this length in the fund's history.Ended higherWindows that ended higher. The share of all the windows of this length in which the NAV ended above where it started.
1 year1,062 windows−15.3%+16.6%+64.8%73.6%
3 years569 windows+12.3%+20.2%+27.6%100.0%
5 yearsLaunched 2 Jul 2021, needs 6 years of history
Every 3-year window ended higher than it started.
Nippon India Nifty Pharma ETF SIP returns
₹10,000 on the 1st of every month, valued at the NAV of 22 Oct 2026
| Period | InvestedAmount invested. ₹10,000 on the 1st of every month, or the next day the fund priced, added up over the period. | Value todayValue today. What the units bought by every instalment are worth at the latest NAV. | Invested against value today | SIP returnSIP return (XIRR). The yearly rate that, applied to each monthly instalment from the day it was invested, gives the value of all the units today. | After stamp dutySIP return after stamp duty. The same SIP return with stamp duty of 0.005% taken from every instalment since 1 Jul 2020, so ₹10,000 buys ₹9,999.50 of units. | Stamp dutyStamp duty paid. The stamp duty on all the instalments, in rupees: 0.005% of each purchase made since 1 Jul 2020. |
|---|---|---|---|---|---|---|
| 1 year12 instalments | ₹1,20,000 | ₹1,29,366₹1,29,360 after stamp duty | +15.55% | +15.54% | ₹6 | |
| 3 years36 instalments | ₹3,60,000 | ₹4,36,864₹4,36,842 after stamp duty | +13.20% | +13.19% | ₹18 | |
| 5 years60 instalments | ₹6,00,000 | ₹9,12,261₹9,12,215 after stamp duty | +16.94% | +16.93% | ₹30 | |
| Since Jul 202163 instalments | ₹6,30,000 | ₹9,66,714₹9,66,665 after stamp duty | +16.43% | +16.43% | ₹32 |
10 years: Launched 2 Jul 2021, needs 10 years of history.
Risk ratios
NAV to 22 Oct 2026
How much the NAV moves
Standard deviationStandard deviation. How far the fund's monthly returns spread around their average, stated as a yearly figure: the wider the spread, the more the NAV moves.16.19%
Downside deviationDownside deviation. Standard deviation counting only the months in which the fund lost money, stated as a yearly figure.8.72%
Sharpe ratioSharpe ratio. The monthly return above the 91-day Treasury bill yield, divided by its standard deviation and stated for a year: the extra return for each unit of movement in the NAV.0.86
Sortino ratioSortino ratio. The monthly return above the 91-day Treasury bill yield, divided by how far it fell below that yield and stated for a year: the extra return for each unit of movement on the way down.1.44
Against Nifty Pharma TRI
BetaBeta. How much the fund's monthly return moved for each 1% move in its benchmark: 1 moves with it, below 1 moves less.1.00
AlphaAlpha. The yearly return the fund made beyond what its beta to the benchmark accounts for.−0.29 pts
R-squaredR-squared. The share of the fund's monthly movement that its benchmark's movement explains, from 0 to 100.100.0
CorrelationCorrelation. How closely the fund's monthly returns moved in step with its benchmark's, from minus 1 (always opposite) to 1 (always together).1.00
Upside captureUpside capture. The fund's return in the months its benchmark rose, as a percentage of the benchmark's return in those months.99.5%
Downside captureDownside capture. The fund's return in the months its benchmark fell, as a percentage of the benchmark's fall in those months.100.6%
Largest falls
| Largest over | FallLargest fall. The biggest drop in NAV from a high to the low that followed, before the NAV went back above that high. | High on | Low on | Back at the highBack at the high. The first day the NAV closed at or above the high it had fallen from. |
|---|---|---|---|---|
| 1 year | −7.53% | 7 Jan 2026 | 1 Feb 2026 | 26 Feb 2026 |
| 3 years | −16.55% | 9 Oct 2024 | 28 Feb 2025 | 6 May 2026 |
| 5 years | −17.72% | 31 Dec 2021 | 13 Mar 2023 | 19 Jul 2023 |
| Since Jul 2021 | −20.98% | 4 Oct 2021 | 13 Mar 2023 | 27 Jul 2023 |
Portfolio turnover, per cent of assets a year
- TurnoverPortfolio turnover. How much of the portfolio the fund bought or sold over the last year, as a share of its assets, as the fund house states it.
Highest 39.0% in May 2026
Tracking error
Against Nifty Pharma TRI, as on 30 Sep 2026.
Against its index, by window
| Measure | This fund |
|---|---|
| Tracking errorTracking error. How much an index fund's daily returns differed from its index's, stated as a yearly figure. | 0.02% |
| Difference, 1 yearTracking difference. The index fund's return less its index's return over the same period; the fund's costs make it negative. | −0.30 pts |
| Difference, 3 years | −0.31 pts |
| Difference, 5 years | −0.26 pts |
| Difference since launch | −0.28 pts |
Difference: the fund's return less the index's, in percentage points.
Premium or discount to NAV, each session, PHARMABEES
- PremiumPremium or discount. How far the ETF's closing price on the exchange was above or below its NAV the same day: the close divided by that day's NAV, less one. Above the NAV is a premium, below it a discount.
Highest +0.50%, 30 Sep 2026.Lowest −0.48%, 21 Oct 2026.
Nippon India Nifty Pharma ETF portfolio
Portfolio disclosed for 30 Sep 2026.
Holdings on 30 Sep 2026
| Large, mid and small cap. Companies ranked by average market value over six months: the first 100 are large cap, the next 150 mid cap, the rest small cap, by the list in force for the portfolio's month. | Weight in the fund. The holding's market value on the portfolio date as a share of the fund's net assets. | Held since. The first month end of the fund's current run of holding this position; marked "or earlier" where that month is the fund's first portfolio on record or the first after a gap in its portfolios. | |||
|---|---|---|---|---|---|
| Sun Pharmaceutical IndustriesPharmaceuticals & Biotechnology | Large cap13th | 19.50% | 338.68 | 18,64,349 | Jul 2021or earlier |
| Divi's LaboratoriesPharmaceuticals & Biotechnology | Large cap50th | 11.97% | 207.93 | 2,23,780 | Jul 2021or earlier |
| Laurus LabsPharmaceuticals & Biotechnology | Mid cap171st | 7.82% | 135.78 | 6,85,768 | Sep 2021 |
| CiplaPharmaceuticals & Biotechnology | Large cap99th | 7.68% | 133.37 | 9,90,875 | Jul 2021or earlier |
| Dr. Reddy's LaboratoriesPharmaceuticals & Biotechnology | Mid cap104th | 7.62% | 132.40 | 10,73,802 | Jul 2021or earlier |
| Torrent PharmaceuticalsPharmaceuticals & Biotechnology | Large cap61st | 7.16% | 124.37 | 2,59,104 | Jul 2021or earlier |
| LupinPharmaceuticals & Biotechnology | Mid cap105th | 5.00% | 86.83 | 4,27,699 | Jul 2021or earlier |
| Aurobindo PharmaPharmaceuticals & Biotechnology | Mid cap138th | 4.69% | 81.36 | 4,86,612 | Jul 2021or earlier |
| Glenmark PharmaceuticalsPharmaceuticals & Biotechnology | Mid cap176th | 3.56% | 61.89 | 2,65,105 | Sep 2021 |
| Alkem LaboratoriesPharmaceuticals & Biotechnology | Mid cap164th | 3.16% | 54.82 | 1,06,169 | Jul 2021or earlier |
| Zydus LifesciencesPharmaceuticals & Biotechnology | Mid cap114th | 2.92% | 50.70 | 4,36,319 | Jul 2021or earlier |
| Mankind PharmaPharmaceuticals & Biotechnology | Mid cap119th | 2.88% | 49.96 | 1,99,532 | Mar 2024 |
| IPCA LaboratoriesPharmaceuticals & Biotechnology | Mid cap229th | 2.71% | 47.14 | 2,44,621 | Jan 2022 |
| BioconPharmaceuticals & Biotechnology | Mid cap173rd | 2.62% | 45.44 | 12,27,131 | Jul 2021or earlier |
| Gland PharmaPharmaceuticals & Biotechnology | Small cap261st | 2.34% | 40.69 | 1,40,334 | Sep 2021 |
Weight is per cent of the fund's net assets; value in ₹ crore. 1 line filed with no weight is listed without one.
Cash and receivables on 30 Sep 2026
| Weight in the fund. The holding's market value on the portfolio date as a share of the fund's net assets. | ||
|---|---|---|
| Triparty Repo | 0.18% | 3.16 |
| Net Current Assets | −0.12% | −2.55 |
| Cash Margin - CCIL | – | 0.02 |
Weight is per cent of the fund's net assets; value in ₹ crore. 1 line filed with no weight is listed without one.
- Largest holdingLargest holding. The share of the fund in its single largest position, cash and futures not counted as positions.
- 19.50%Sun Pharmaceutical Industries
- Top 5 holdingsTop 5 holdings. The share of the fund held in its five largest positions.
- 54.59%
- Top 10 holdingsTop 10 holdings. The share of the fund held in its ten largest positions.
- 78.16%
- Effective holdingsEffective number of holdings. The number of equal-sized positions that would be as concentrated as the fund's actual weights.
- 11.4Taken over 99.94% of the fund
Asset allocation
Asset allocation. What the fund owns, by kind of asset, each as a share of its net assets; futures and options are shown beside it, not in it, since they are contracts rather than assets bought.- Indian shares99.94%
- Cash and receivables0.06%
Per cent of the fund's net assets.
Large, mid and small cap
Large, mid and small cap. Companies ranked by average market value over six months: the first 100 are large cap, the next 150 mid cap, the rest small cap, by the list in force for the portfolio's month.- Large cap46.34%
- Mid cap46.11%
- Small cap7.55%
Per cent of the fund's Indian shares. By the list for the six months to Jun 2026.
Sector allocation
Sector weight. The fund's shares grouped by the business each company is in, less the futures sold on them, each group as a share of the fund's net assets.1sector
- Healthcare99.94%
Per cent of the fund's net assets, less the futures sold on its shares, Sep 2026.
Sector allocation month by month
| 13 months | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Healthcare20 companies | 99.94% | 99.95% | 99.78% | 99.90% | 99.95% | 99.98% | 99.97% | 99.90% | 99.96% | 99.94% | 99.98% | 99.97% |
Per cent of the fund's net assets, less the futures sold on its shares, at each month end, Oct 2025 to Sep 2026; the line runs from Sep 2025.
Bought and sold
Sep 2026 against Aug 2026, position by position.
Positions changed, month by month
- New
- Added
- Trimmed
- Sold out
- New positionsNew positions. Holdings in this month's portfolio that were not in the month before.
- 0
- Sold outSold out. Holdings in last month's portfolio that are gone from this one, other than a bond or deposit repaid on its due date.
- 0
- Added toAdded to. Holdings with more units than the month before. Where the fund states no units, a weight that rose by more than a tenth.
- 19
- TrimmedTrimmed. Holdings with fewer units than the month before. Where the fund states no units, a weight that fell by more than a tenth.
- 1
- UnchangedUnchanged. Holdings with the same number of units as the month before. Their weight can still move with the price.
- 0
- Traded at leastTraded at least. The smaller of the weight bought in new positions and the weight sold out of old ones, cash left out: the least the fund must have bought and sold in the month.
- 0.00%
- Weight that movedWeight that moved. Half the sum of every position's change in weight between the two month ends, new and sold positions included; price moves alone raise it.
- 2.26%
Changes in Sep 2026
| What changed. New: not held the month before. Added or trimmed: more or fewer units than the month before, or, where no units are stated, a weight that moved by more than a tenth. Sold out: held the month before, gone now. Matured: a bond or deposit whose repayment date fell between the two portfolios, so it was repaid rather than sold (one sold in its last days reads the same). | Change in weight. The holding's weight this month less its weight the month before, in percentage points; a price move alone changes it. | ||||
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | Added | 19.50% | 20.75% | −1.25 pts | +23,565 |
| Dr. Reddy's Laboratories | Added | 7.62% | 6.95% | +0.67 pts | +14,091 |
| Laurus Labs | Added | 7.82% | 7.36% | +0.46 pts | +9,367 |
| Biocon | Trimmed | 2.62% | 2.90% | −0.28 pts | −13,184 |
| Lupin | Added | 5.00% | 5.25% | −0.25 pts | +5,525 |
| Wockhardt | Added | 1.77% | 1.54% | +0.23 pts | +1,890 |
| Mankind Pharma | Added | 2.88% | 2.70% | +0.18 pts | +2,731 |
| Torrent Pharmaceuticals | Added | 7.16% | 7.34% | −0.18 pts | +4,105 |
| Ajanta Pharma | Added | 1.67% | 1.50% | +0.17 pts | +7,039 |
| Cipla | Added | 7.68% | 7.83% | −0.15 pts | +12,685 |
| Sai Life Sciences | Added | 2.14% | 1.99% | +0.15 pts | +3,671 |
| Glenmark Pharmaceuticals | Added | 3.56% | 3.69% | −0.13 pts | +3,356 |
| Abbott India | Added | 1.43% | 1.33% | +0.10 pts | +121 |
| Divi's Laboratories | Added | 11.97% | 11.88% | +0.09 pts | +2,839 |
| Alkem Laboratories | Added | 3.16% | 3.08% | +0.08 pts | +4,432 |
Weights are per cent of the fund's net assets; a change in weight is in percentage points.
Portfolio overlap
Funds holding the most of the same securities, by weight.
Closest funds in the category
| Portfolio overlap. The share of the two funds' portfolios that is the same: for every holding they share, the smaller of its two weights, added up. | Shared holdings. The number of securities both funds hold, cash and futures left out. | |
|---|---|---|
| ICICI Prudential Nifty Healthcare ETFICICI Prudential Mutual Fund | 81.12% | 16 |
| DSP Nifty Healthcare ETFDSP Mutual Fund | 81.09% | 16 |
| Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 61.15% | 20 |
| Nippon India Nifty India Manufacturing ETFNippon India Mutual Fund | 18.25% | 10 |
| Motilal Oswal Nifty India Manufacturing ETFMotilal Oswal Mutual Fund | 18.22% | 10 |
| HDFC Nifty Growth Sectors 15 ETFHDFC Mutual Fund | 16.64% | 3 |
| Motilal Oswal Nifty Midcap150 Momentum 50 ETFMotilal Oswal Mutual Fund | 15.63% | 6 |
| SBI Nifty Midcap 150 Momentum 50 ETFSBI Mutual Fund | 15.63% | 6 |
| Nippon India ETF Nifty 50 Shariah BeESNippon India Mutual Fund | 14.50% | 3 |
| Motilal Oswal BSE Low Volatility ETFMotilal Oswal Mutual Fund | 14.48% | 5 |
Portfolios for Sep 2026. Overlap is per cent of the portfolio the two funds hold in common.
Nippon India Nifty Pharma ETF expense ratio and exit load
Per cent of the money invested, a year. Each month shows its last day filed; the parts were redefined from Apr 2026.
- 30-day averageExpense ratio, 30-day average. The total expense ratio averaged over the last 30 days the fund filed it, which evens out the day-to-day moves in brokerage and levies.
- 0.23%Over the last 30 days filed
Total expense ratio, month by month
Expense ratio highest 0.24%, Aug 2026.Expense ratio lowest 0.19%, Jan 2023.
What the expense ratio is made of
| Part | A year |
|---|---|
| Base expense ratioBase expense ratio. The part of the expense ratio that pays the fund house and the distributor, before brokerage, transaction costs, levies and GST. | 0.18% |
| Brokerage | None |
| Transaction costs | None |
| Statutory levies | 0.05% |
Per cent of assets a year, filed for 19 Oct 2026. The parts add up to that day's total.
Nippon India Nifty Pharma ETF AUM
₹ crore, every plan of the fund together.
- Average assetsAverage assets under management. The money the fund managed, averaged over every day of the quarter, added up across its plans.
- ₹1,700 CrQuarter to Sep 2026
Average assets by quarter
The latest quarter is the largest since the quarter to Sep 2021.
Assets at each month end
Highest ₹1,761 Cr, Aug 2026.Lowest ₹88 Cr, Jul 2022.
Nippon India Nifty Pharma ETF fund managers
Managers now
| Manager | Return in the manager's time. The change in the plan's NAV from the day the manager took the fund over to the latest NAV; past a year, the yearly rate that would compound to the same change. | Benchmark over the same days. The change in the fund's benchmark index over the same days as the manager's return, worked out the same way, with the dividends of the index's companies added back. | Difference from the benchmark. The fund's return in the manager's time less its benchmark's over the same days, in percentage points. | Portfolio changed after the handover. How much of the portfolio was different three months after the manager took over: half the sum of every holding's change in weight, with each side's holdings scaled to add up to 100 so a move into cash does not count. | Portfolio changed before the handover. The same measure over the three months before the manager took over, since portfolios change anyway. | Assets the manager runs. The latest monthly size of every fund the manager runs now, added up; a fund run with others counts in full for each of its managers, and the line under it counts only the funds they run alone. | ||
|---|---|---|---|---|---|---|---|---|
| Jitendra TolaniPrimary | Feb 2025 | +12.32%a year | +12.58% | −0.26 pts | 2.6% | 1.9% | 21 | ₹37,372 Cr₹37,372 Cr alone |
Returns are the direct plan's growth NAV, from the day each took over to the latest NAV, beside the benchmark over the same days.
Other funds they run
| Fund | Return in the manager's time. The change in the plan's NAV from the day the manager took the fund over to the latest NAV; past a year, the yearly rate that would compound to the same change. | Benchmark over the same days. The change in the fund's benchmark index over the same days as the manager's return, worked out the same way, with the dividends of the index's companies added back. | Difference from the benchmark. The fund's return in the manager's time less its benchmark's over the same days, in percentage points. | ||
|---|---|---|---|---|---|
| CPSE ETFJitendra Tolani | Feb 2025 | +3.26%a year | +3.32% | −0.06 pts | ₹18,645 Cr |
| Nippon India Silver ETF FOFJitendra Tolani | Feb 2025 | +58.26%a year | – | – | ₹4,354 Cr |
| Nippon India ETF Nifty PSU Bank BeESJitendra Tolani | Feb 2025 | +17.05%a year | +17.72% | −0.67 pts | ₹3,932 Cr |
| Nippon India ETF Nifty ITJitendra Tolani | Feb 2025 | −13.38%a year | −13.18% | −0.19 pts | ₹3,425 Cr |
| Nippon India Nifty 500 Momentum 50 Index FundJitendra Tolani | Feb 2025 | +2.60%a year | +2.98% | −0.38 pts | ₹1,277 Cr |
| Nippon India Nifty Alpha Low Volatility 30 Index FundJitendra Tolani | Feb 2025 | −2.15%a year | −1.57% | −0.58 pts | ₹1,169 Cr |
| Nippon India Nifty 50 Value 20 Index FundJitendra Tolani | Feb 2025 | −5.94%a year | −5.53% | −0.41 pts | ₹708 Cr |
| Nippon India Nifty Auto ETFJitendra Tolani | Feb 2025 | +6.98%a year | +7.29% | −0.32 pts | ₹452 Cr |
| Nippon India Nifty 500 Equal Weight Index FundJitendra Tolani | Feb 2025 | +5.12%a year | +5.79% | −0.67 pts | ₹450 Cr |
| Nippon India Nifty IT Index FundJitendra Tolani | Feb 2025 | −13.81%a year | −13.57% | −0.24 pts | ₹240 Cr |
Up to ten funds a manager, largest first. Returns are the direct plan's.
Changes to the fund
Newest first.
2026
- 1 AprExpenseExpense ratio stated under the new rules: a base ratio, with brokerage, levies and GST on top
Risk level by month
| Months | FundRiskometer. The fund's own risk label on SEBI's six-step scale, from Low to Very High, set from what the fund holds and reviewed every month. | BenchmarkBenchmark's risk level. The riskometer level of the fund's benchmark index for the same month, on the same six-step scale as the fund's own. |
|---|---|---|
| Jun 2022 to Aug 202651 months | Very High | Very HighNifty Pharma TRI |
The riskometer at each month end, the fund's and its benchmark's. A month with none on record is left out.
Fund details
Objective
The investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the NIFTY Pharma Index before expenses, subject to tracking errors. However, there can be no assurance or guarantee that the investment objective of the Scheme will be achieved.
Asset allocation
Securities constituting securities constituting Nifty Pharma Index - 95% to 100%, Money Market Instruments including TriParty Repo on governement securities or T-Bills, cash & cash equivalents or Liquid Schemes - 0% to 5%.
Type of scheme
An open ended scheme replicating/ tracking NIFTY Pharma Index
- BenchmarkBenchmark. The index the fund house chose to measure the fund against, in its total return form, with dividends added back.
- Nifty Pharma TRI
- Risk level at launchRiskometer. The fund's own risk label on SEBI's six-step scale, from Low to Very High, set from what the fund holds and reviewed every month.
- Very High
- New fund offer
- 21 Jun 2021 to 28 Jun 2021
- Units first allotted
- 2 Jul 2021
- Open for sale again
- 7 Jul 2021
- Price at the offer
- ₹10 a unit
- Minimum at the offer
- ₹1,000
Plans and codes
| Plan | AMFI code | ISIN | First NAV |
|---|---|---|---|
| Direct Growth | 149008 | INF204KC1089 | 6 Jul 2021 |
This fund
- Scheme information document (opens in a new tab)The fund's objective, terms, costs and risks in full
Factsheet
- Fundamentals \ E-Factsheet: October 2026 (opens in a new tab)Nippon India Mutual Fund, Sep 2026
Statement of additional information
- SAI Nippon India Mutual Fund (opens in a new tab)Nippon India Mutual Fund, Oct 2026
Annual report
- Abridged Scheme Account 2025-2026 - ight face intermittent issues with NetBanking payment mode during Purchase transaction on our Digital assets. Kindly use an alternative payment mode. Regret the inconvenience caused. --> --> --> Custom Title Abridged Scheme Account 2025 - 26 Page Content 1. Consol (opens in a new tab)Nippon India Mutual Fund, Mar 2026
- Abridged Scheme Account 2025-2026 - 2. Consolidated Debt Schemes (opens in a new tab)Nippon India Mutual Fund, Mar 2026
- Abridged Scheme Account 2025-2026 - 3. Consolidated Exchange Traded Funds (opens in a new tab)Nippon India Mutual Fund, Mar 2026
- Abridged Scheme Account 2025-2026 - 4.Consolidate Interval Funds and Fixed Maturity Plans (opens in a new tab)Nippon India Mutual Fund, Mar 2026
Riskometer disclosure
- Download (opens in a new tab)Nippon India Mutual Fund, Mar 2026
Portfolio overlap disclosure
- Portfolio Overlap (opens in a new tab)Nippon India Mutual Fund, Sep 2026
- Portfolio-Overlap-30-Sep-2026 (opens in a new tab)Nippon India Mutual Fund, Sep 2026